Table 2.
Patient characteristics
| Patient characteristics | Total N = 30 |
IG n = 17 |
CG n = 13 |
|---|---|---|---|
| Age (years) | |||
| Mean (SD) | 68 (12.2) | 69 (9.7) | 67 (15.3) |
| Median (range) | 69 (38–90) | 68 (48–82) | 70 (38–90) |
| Age groups, years (n (%)) | |||
| ≤ 49 | 3 (10) | 1 (6) | 2 (15) |
| 50–59 | 4 (13) | 2 (12) | 2 (15) |
| 60–69 | 9 (30) | 7 (41) | 2 (15) |
| 70–79 | 10 (33) | 5 (29) | 5 (38) |
| 80–89 | 3 (10) | 2 (12) | 1 (8) |
| ≥ 90 | 1 (3) | 0 (0) | 1 (8) |
| Gender (n (%)) | |||
| Male | 23 (77) | 14 (82) | 9 (69) |
| Female | 7 (23) | 3 (18) | 4 (31) |
| WHO performance status (n (%)) | |||
| 0–1 | 25 (83) | 13 (77) | 12 (93) |
| ≥ 2 | 5 (17) | 4 (24) | 1 (8) |
| Planned treatment (n (%)) | |||
| HDT-SCTa | 18 (60) | 10 (59) | 8 (62) |
| Not HDT-SCT | 12 (40) | 7 (41) | 5 (38) |
| Bone disease, in general (n (%)) | |||
| No | 10 (33) | 3 (18) | 7 (54) |
| Yes | 20 (67) | 14 (82) | 6 (46) |
| Bone disease with restriction for tests or exercise, n = 20 (n (%)) | |||
| No | 10 (50) | 9 (64) | 1 (17) |
| Yes | 10 (50) | 5 (36) | 5 (83) |
aHDT-SCT high-dose therapy with stem cell transplantation